These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 10806600)

  • 1. Pharmacokinetics, pharmacodynamics, and safety of microencapsulated octreotide acetate in healthy subjects.
    Chen T; Miller TF; Prasad P; Lee J; Krauss J; Miscik K; Kalafsky G; McLeod JF
    J Clin Pharmacol; 2000 May; 40(5):475-81. PubMed ID: 10806600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population PK and PK/PD modelling of microencapsulated octreotide acetate in healthy subjects.
    Zhou H; Chen TL; Marino M; Lau H; Miller T; Kalafsky G; McLeod JF
    Br J Clin Pharmacol; 2000 Dec; 50(6):543-52. PubMed ID: 11136293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of chronic treatment with octreotide nasal powder on serum levels of growth hormone, insulin-like growth factor I, insulin-like growth factor binding proteins 1 and 3 in acromegalic patients.
    Invitti C; Fatti L; Camboni MG; Porcu L; Danesi L; Delitala G; Cavagnini F
    J Endocrinol Invest; 1996 Sep; 19(8):548-55. PubMed ID: 8905479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sandostatin LAR in acromegaly: a 6-week injection interval suppresses GH secretion as effectively as a 4-week interval.
    Biermasz NR; van den Oever NC; Frölich M; Arias AM; Smit JW; Romijn JA; Roelfsema F
    Clin Endocrinol (Oxf); 2003 Mar; 58(3):288-95. PubMed ID: 12608933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Octreotide s.c. depot provides sustained octreotide bioavailability and similar IGF-1 suppression to octreotide LAR in healthy volunteers.
    Tiberg F; Roberts J; Cervin C; Johnsson M; Sarp S; Tripathi AP; Linden M
    Br J Clin Pharmacol; 2015 Sep; 80(3):460-72. PubMed ID: 26076191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relative Bioavailability of a Single 4-mg Dose of Somatropin Administered by Subcutaneous Injection or by Needle-free Device and Coadministered With the Growth Hormone Inhibitor Octreotide Acetate in Healthy Adult Subjects.
    Brimhall DB; Petri N; D'Angelo P
    Clin Ther; 2018 May; 40(5):741-751. PubMed ID: 29699852
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of monthly intramuscular injections of Sandostatin LAR with multiple subcutaneous injections of octreotide in the treatment of acromegaly; effects on growth hormone and other markers of growth hormone secretion.
    Hunter SJ; Shaw JA; Lee KO; Wood PJ; Atkinson AB; Bevan JS
    Clin Endocrinol (Oxf); 1999 Feb; 50(2):245-51. PubMed ID: 10396369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of the somatostatin analog octreotide acetate on circulating insulin-like growth factor-1 and related peptides in patients with non-metastatic castration-resistant prostate cancer: results of a phase II study.
    Friedlander TW; Weinberg VK; Small EJ; Sharib J; Harzstark AL; Lin AM; Fong L; Ryan CJ
    Urol Oncol; 2012; 30(4):408-14. PubMed ID: 20884247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical pharmacodynamic effects of the growth hormone receptor antagonist pegvisomant: implications for cancer therapy.
    Yin D; Vreeland F; Schaaf LJ; Millham R; Duncan BA; Sharma A
    Clin Cancer Res; 2007 Feb; 13(3):1000-9. PubMed ID: 17289896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lunelle monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension): steady-state pharmacokinetics of MPA and E2 in surgically sterile women.
    Rahimy MH; Ryan KK; Hopkins NK
    Contraception; 1999 Oct; 60(4):209-14. PubMed ID: 10640167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness, pharmacokinetics, and safety of a new sustained-release leuprolide acetate 3.75-mg depot formulation for testosterone suppression in patients with prostate cancer: a Phase III, open-label, international multicenter study.
    Marberger M; Kaisary AV; Shore ND; Karlin GS; Savulsky C; Mis R; Leuratti C; Germa JR
    Clin Ther; 2010 Apr; 32(4):744-57. PubMed ID: 20435244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly.
    Chanson P; Boerlin V; Ajzenberg C; Bachelot Y; Benito P; Bringer J; Caron P; Charbonnel B; Cortet C; Delemer B; Escobar-Jiménez F; Foubert L; Gaztambide S; Jockenhoevel F; Kuhn JM; Leclere J; Lorcy Y; Perlemuter L; Prestele H; Roger P; Rohmer V; Santen R; Sassolas G; Scherbaum WA; Schopohl J; Torres E; Varela C; Villamil F; Webb SM
    Clin Endocrinol (Oxf); 2000 Nov; 53(5):577-86. PubMed ID: 11106918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and pharmacodynamics of GH: dependence on route and dosage of administration.
    Keller A; Wu Z; Kratzsch J; Keller E; Blum WF; Kniess A; Preiss R; Teichert J; Strasburger CJ; Bidlingmaier M
    Eur J Endocrinol; 2007 Jun; 156(6):647-53. PubMed ID: 17535864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Somatuline(R) Autogel(R), a new formulation of lanreotide for the treatment of acromegalic patients].
    Caron P
    Ann Endocrinol (Paris); 2002 Apr; 63(2 Pt 3):2S19-24. PubMed ID: 12037499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Administration of human recombinant insulin-like growth factor-I in critically ill patients.
    Yarwood GD; Ross RJ; Medbak S; Coakley J; Hinds CJ
    Crit Care Med; 1997 Aug; 25(8):1352-61. PubMed ID: 9267949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome.
    Rubin J; Ajani J; Schirmer W; Venook AP; Bukowski R; Pommier R; Saltz L; Dandona P; Anthony L
    J Clin Oncol; 1999 Feb; 17(2):600-6. PubMed ID: 10080605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic dose-extension of octreotide LAR: the importance of individual tailoring of treatment in patients with acromegaly.
    Turner HE; Thornton-Jones VA; Wass JA
    Clin Endocrinol (Oxf); 2004 Aug; 61(2):224-31. PubMed ID: 15272918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis.
    Brown VA; Patel KR; Viskaduraki M; Crowell JA; Perloff M; Booth TD; Vasilinin G; Sen A; Schinas AM; Piccirilli G; Brown K; Steward WP; Gescher AJ; Brenner DE
    Cancer Res; 2010 Nov; 70(22):9003-11. PubMed ID: 20935227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women.
    Khorram O; Laughlin GA; Yen SS
    J Clin Endocrinol Metab; 1997 May; 82(5):1472-9. PubMed ID: 9141536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic properties of once-daily oral low-dose mesylate salt of paroxetine (LDMP 7.5 mg) following single and multiple doses in healthy postmenopausal women.
    Cristina Castelli M; Bhaskar S; Lippman J
    Clin Ther; 2013 Jun; 35(6):862-9. PubMed ID: 23795577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.